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It is an established concept in modern can-
cer research that structural and functional
alterations of cellular genes are instrumen-
tal in the transformation of a normal cell
into a malignant phenotype. Although to
date no causal relationship has been proved
to link steroid-hormone effects to the
induction ofchromosomal alterations in an
animal system, steroid hormones have been
shown to be capable ofproducing chromo-
somal abnormalities in cultured cells (1,2).
In addition, Banduhn and Obe (3) showed
that both diethylstilbestrol (DES) and
estradiol are capable of inducing genomic
mutations in cultured cells, and Wheeler et
al. (4) showed that estradiol and DES are
potent inhibitors of mitosis in in vitro cell
cultures. A similar study by Tsutsui et al.
(5) suggested that estrogen can induce two
types of genetic changes, one involving
numerical chromosome change (aneu-
ploidy) with no evident DNA damage and
another associated with structural chromo-
somal aberrations induced by estrogen cat-
echol metabolites. Hillbertz-Nilsson and
Forsberg (6) reported estrogen-induced
aneuploidy in the epithelial cells from the
uterine cervix of a neonatal mouse. Their
report, along with those ofEndo et al. (7)
and Hajek et al. (8,9), suggests the possi-
bility that perinatal exposure to estrogen
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results in chromosomal aberrations in the
same target tissues in which neoplasia occurs
after the in vivoadministration ofestrogen.
Evolution of Malignancy
Experimental studies ofcarcinogenesis and
clinical evidence suggest that the develop-
ment of a malignant tumor is a gradual
evolutionary process during which tumor
cells progressively acquire permanent quali-
tatively different characteristics (10).
Genetic instability of tumor cells has been
found to be greatly enhanced over that of
normal cells, and amplification of DNA
may be one of the mechanisms that leads
to the emergence ofclonal populations that
have increasingly malignant properties
(11,12). Amplification of genes could
enable the host cells to escape growth con-
trol, to become mobile and invasive, or to
escape immune surveillance. For instance,
trisomy for chromosome 7 appears to be
one ofthe nonrandom primary changes in
gynecologic adenocarcinomas that is appar-
ently associated with the early clinical
stages of the disease. From the molecular
viewpoint, chromosome 7 has several
growth factor genes (e.g., epidermal growth
factor [EGF] receptor), many genes for cell
surface proteins, and at least two human
protooncogenes (i.e., HER2/neu and met).
If the extra chromosome 7 results in
increased secretion ofcellular growth factors,
this could be an initial step in malignant
transformation. Information supporting
the exposure to steroid hormones and
genetic alterations that ultimately lead to
the development of malignant tumor has
been gradually forthcoming.
Role of Estrogenic
Compounds as Potential
Initiators and Promoters of
Hormonal Carcinogenesis
Using a mouse skin tumorigenesis model,
Conti et al. (13) and Aldaz et al. (14)
reported a positive correlation between
histological and cytogenetic analysis with
more aggressive and atypical tumors. They
showed that 10 to 20 weeks ofexposure to
a promoter stimulated the progression ofa
papilloma (benign diploid lesion) to a
hyperdiploid (neoplastic) lesion. Their
results suggest that aneuploidy may play a
mechanistic role in the sequence of events
that lead to neoplasia in epithelial tissue. It
has also been suggested that the chemical
induction of skin tumors in mice can be
subdivided into at least three stages: initia-
tion, promotion, and tumor development
(14). The progression from initiation to
carcinoma is thought to involve the clonal
expansion of initiated epidermal cells,
which results in the formation of benign
tumors. The conversion of benign tumors
to carcinomas is thought to require an
additional cellular (i.e., genomic) change.
The hormonal induction of tumors may
involve a similar process. Unlike chemical
induction in the mouse skin tumorigenesis
model, perinatal exposure to estrogen dur-
ing a critical period during the develop-
ment of the neonatal mouse resulted in a
state of continuous proliferation of cer-
vicovaginal epithelium, even in the absence
ofestrogen. However, similar to the chemi-
cal induction of skin tumors, perinatal
exposure to estrogen may result in the
selection of a clonal population. It is the
development of cervicovaginal tumors in
intact mice that indicates that a particular
clonal population may be under the
influence ofestrogen (Figure 1).
The development of this particular
clonal population and the subsequent
development of tumors is time dependent
(15) (Table 1). In addition, perinatal expo-
sure to estrogen before 3 days after birth,
followed by continuous secondary estrogen
administration beginning at 10 days ofage,
reduces the latency period required for the
nuclear DNA content ofthe cervicovaginal
epithelium to increase (9). These data indi-
cate that, like the human fetus, a critical
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period exists in mice for the induction of
cervicovaginal abnormalities. The critical
period for the induction of nuclear DNA
changes appears to be similar to the critical
period for the induction of cervicovaginal
tumors. In addition to the numerical chro-
mosomal changes, a change in the expres-
sion of certain proteins occurs (Figure 1).
In our neonatal mouse model after expo-
sure to estrogen, the expression of
HER2/neu (Figure 2) and c-fos was altered
(16). Interestingly, the c-fos protein is
considered to be a master switch because it
is part of the primary genomic response to
stimulation by extracellular signals. It
transduces these signals by regulating a
number of secondary genes, which remain
to be identified. Perinatal exposure to estro-
gen during a critical period results in an
alteration in the expression ofc-fsand thus
links hormonal carcinogenesis to the manip-
ulation ofa keyfunction in the regulation of
cell behavior (16). Recent studies by Liehr
et al. (17) demonstrated a similar effect in
hamster kidneys exposed to estrogens.
J. Gorski's presentation asked whether
the variety of effects induced by estrogen
exposure was due to a nontraditional effect
ofhormones or was it related to the classic
estrogen receptor (ER) system. Gorski
reported that the ER system exists in a 10-
day rat fetus whether it is a future male or
female rat. Western blots done on protein
extracts from the reproductive tracts of
both male and female rat fetuses on days
15, 17, and 19 postconception showed a
marked increase of ER in the female
Exogenous/andogenous factors
Ezand otheragents
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Cancer
Table 1. Defining critical period for
induced tumordevelopment.
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Figure 1. Multistep hormonal carcinogenesis.
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of animals (%) with D. Crews and associates stated in their pres-
:ovaginal lesions entation that exposure to specific environ-
1/17 (47%) mental stimuli or physical conditions
1/22 (45%) during developmental stages (i.e., embry-
1/24 (8%) onic and fetal) can influence the expression
/20 (0%) of genes such as the aromatase and reduc-
1/23 (0%) tase enzymes. They set out to determine
d (sc) daily with 25 how the environmental stimulus of tem-
sesame oil. bAfter perature affected the cellular events con-
trolling sex determination. Using turtles,
they found that a precise relationship
existed between the temperature at which
In contrast, the turtle eggs were incubated and the
sed with age in male:female ratio of turtles born. With a
sensitive proce- variance of only about 1°C, Crews found
Lse-polymerase that only male turtles hatched from eggs
the rat fetus on incubated at low temperatures and only
1- and 2-cell- females hatched from eggs incubated at
ignal that indi- higher temperatures; there were no
message. They hermaphrodites. His results suggested the
ssage was both existence of a mechanism that controlled
d by the oocyte steroid hormone feedback, but was itself
to the embryo. controlled by temperature. How does the
sappeared and physical stimulus of temperature get trans-
een the 5- to 8- ferred into a cellular event? It is known
,as not detected that specific temperature conditions can
Lppeared at the create specific enzyme patterns during this
it experiment sensitive stage ofdevelopment, particularly
ie receptor (PR) involving aromatase and reductase (e.g.,
the early stages, 5a-reductase) activity. Crews' studies indi-
lastocyst stage. cate the possible presence of a temperature-
icate a possible sensitive promoter that acts directly on the
n both endoge- aromatase gene and complementary to the
ire to estrogens reductase gene to influence the production
relopment. of estrogen. That is, the environmental
temperature triggers the action of the
mechanism controlling steroid hormone
feedback and causes these genes to produce
or not produce estrogen.
No/minimal effect In extending his studies to the impact
of direct exposure to environmental estro-
gen on development, Crews found that
only two polychlorinated biphenyl (PCB)
compounds had any effect. Cocktail mix-
tures of PCBs without these two effectors
cells had no influence on enzyme or estrogen
production. In addition, the two effectors
were synergistic.
Effects of Perinatal
Exposure to Estrogen on
Nonreproductive Structures
T. Iguchi discussed the effect of perinatal
exposure to estrogen on both reproductive
No E2 and nonreproductive structures. Perinatal
+I-' treatment of female mice with estrogenic
compounds such as DES induced a contin-
uous proliferation of the vaginal epithe-
lium, even in the absence of estrogen.
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Figure 2. (A) H&E stained slide showing cervicovaginal lesions in a neonatally estrogenized 20-month-old mouse x2O. (B) The same area in A stained for the presence of
HER-21neux20. (C) Highermagnification ofthe highlighted area in B, x40.
Iguchi and associates reported that this
irreversibly changed vaginal epithelium
persistently expressed higher levels ofc-jun
and c-fos mRNAs. Although not consid-
ered to be a reproductive structure, sexual
dimorphism of the pelvis has been
described in several mammals. Iguchi
described sexual dimorphism in the mouse
pelvis and the anococcygeous muscle. They
reported that the pelvic bone is susceptible
to castration, ovariectomization, and the
addition ofexogenous hormones. Neonatal
tamoxifen treatment caused inhibition of
pubic bone calcification, causing this bone
to remain cartilaginous into adulthood.
Iguchi reported that the effect of sex
steroids on the growth ofthe anococcygeous
muscle varied according to gender. In males,
castration reduced the size of the muscle,
whereas the administration of testosterone
resulted in partial restoration. In females,
ovariectomy slightly increased the size ofthe
anococcygeous musde, whereas the admin-
istration ofestrogen decreased the size ofthe
muscle. However, when DES was adminis-
tered neonatally, the muscle was widened,
which again supports the hypothesis that
estrogens have different effects on develop-
ingand adult tissue.
The permanent effects of exposure of
neonatal rodents to steroid hormones have
been the subject of scientific investigation
since the 1930s (18). At the end of the
1960s, evidence began to emerge from
clinical studies that treating pregnant
women with DES for threatened abortion
in the first trimester correlated with the
appearance of vaginal adenocarcinoma in
their young daughters. During the decade
following the description of the initial six
cases of vaginal adenocarcinoma in young
women after exposure to DES or chemi-
cally related hormones in utero, a wealth of
information became available concerning
the pathology and pathogenesis of disor-
ders related to prenatal exposure to these
agents (19). Presently, it is estimated that
in utero DES exposure of the female
human fetus has resulted in approximately
519 documented cases ofvaginal and cervi-
cal clear-cell adenocarcinoma (20). This
represents only a small percentage ofthe as
yet unknown total number of young
women exposed to DES in utero. The pop-
ulation at risk has been estimated to be as
great as 2 million females (21,22).
As reported by R. Newbold, studies of
DES using the neonatal mouse have been
and continue to be productive for a variety
of reasons. She and her associates used the
mouse model to study the effects of DES
and demonstrated that the majority of
DES-related developmental abnormalities
observed in humans could be reproduced in
mice. Conversely, she provided data useful
as clinical guides for as yet unseen or unrec-
ognized human conditions. These effects
may also illustrate potential adverse health
effects from lower potency estrogens.
It is important to consider the role of
estrogens in the environment, especially
their effects on development. For instance,
many organochlorine pollutants such as
PCBs present in the environment have the
ability to weakly bind to the estrogen
receptor (23). However, at present, it is
unknown whether they also have the abil-
ity to induce tumorigenesis as observed for
potent estrogens. Both environmental and
genetic interactions play equally important
roles in human disease.
Developmental Abnormalities
Resulting from Exposure
to Estrogenic Chemicals
Ando et al. (24) demonstrated that estro-
genic chemical compounds can cross the
placenta to the fetus and can be transferred
via breast milk to newborns. In the female
fetus, previous studies have indicated that
the organs most susceptible to develop-
mental effects from endocrine-disrupting
chemicals include the mammary gland, fal-
lopian tubes, uterus, cervix, and vagina
(18). Recent findings demonstrated that
177a-estradiol, a weak estrogen, can cause
reproductive abnormalities similar to those
reported in BALB/c mice exposed perina-
tally to natural and synthetic estrogens.
These findings raise the possibility oflong-
term consequences resulting from early
exposure to weak environmental estrogens
(25). Because of this possibility, exposure
during a critical period of development to
environmental estrogens such as organo-
chlorine pollutants (e.g., PCBs), which
have the ability to bind weakly to the ER,
may induce abnormalities similar to those
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resulting from potent estrogens such as
DES. Are dioxins potent estrogens too?
Dioxins, once thought solely to be
antiestrogenic, represent another family of
ubiquitous environmental pollutants
(26,27) all of which demonstrate a com-
mon mechanism of action. L. Birnbaum's
presentation summarized the potential
developmental toxic effects caused by
dioxin. For instance, dioxin-exposure
syndrome may include any or all ofthe fol-
lowing symptoms: wasting, thymic atro-
phy, fatty liver, enzyme induction, edema,
chloracne, embryo/fetal toxicity, and ter-
atogenicity. The biochemical effects of
dioxin exposure include the induction of
enzymes that are associated with intermedi-
ary metabolism and biotransformation.
Dioxins modulate hormone systems,
including that of the thyroid, and lead to
changes in homeostasis. Dioxin-induced
changes in growth factors lead to altered
growth and development patterns. Dioxins
also produce changes in such protoonco-
genes as c-fos, c-jun, and ras. Interestingly,
these are the same protooncogenes influ-
enced by perinatal exposure to estrogen. In
summary, Birnbaum suggests that dioxins
should be viewed as modulators ofgrowth
and development because they contain
both estrogenic and antiestrogenic proper-
ties. What is interesting is the fact that
dioxins do not interact with the ER to
cause any of the above effects. However,
further study may shed some light on the
complexities ofthese compounds as growth
dysregulators operating through their own
receptor mechanism, AhRs.
In what other tissues could environmen-
tal exposure to estrogenic compounds
potentially result in developmental abnor-
malities? S. Migliaccio and colleagues stud-
ied the effect of DES exposure on the
developmental programming of bone cell
metabolism. Osteoporosis is a condition
that over decades robs the skeleton of
resources until the bone is weak enough to
sustain a spontaneous fracture. In the study
ofER in bone tissue, estrogen was found to
modulate the activity ofbone cells in vitro.
To address the question ofwhether changes
in estrogen levels during development could
affect skeletal characteristics, Migliaccio and
co-workers used the neonatal mouse model
to evaluate the potential effects ofenviron-
mental estrogens on developing bone tissue
(33). What they observed was the effects of
DES on the length of the femur. In addi-
tion, perinatal exposure to DES affected
the density ofthe bone tissue. Basically, the
length ofthe femur decreased and the bone
mass increased. She also observed that
bone is more sensitive to the disruptive
effects of DES at lower levels of exposure.
Although no definitive study has been
done with women exposed to DES in
utero, there have been a few self-reported
cases ofspondylolisthesis.
Summary
The sum of the evidence supports the
necessity to continue to investigate the
developmental effects of estrogenic and
antiestrogenic compounds when exposure
occurs early in life. Additional studies will
answer questions relevant to the molecular
definition ofthe developmental or carcino-
genic effects ofestrogens such as hormone-
induced gene alterations. These studies also
support the need to use the neonatal mouse
model to demonstrate the consequences of
reproductive and nonreproductive stem-cell
exposure to estrogenic compounds.
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